Oulu: T Ala-Kokko; France: CHRU de Tours Hopital Bretonneau, Tours: D Perrotin; CHRU de Limoges Hopital Dupuytren Hospital Les Oudairies Angouleme Hospital ,
Birmingham Heartlands Hospital, Birmingham: G Raghuraman; Guy's and St. Thomas's NHS Foundation Trust: S Drage; Imperial College Healthcare NHS Trust, D Wyncoll; Royal Berkshire Hospital, Reading: A Kapila; Queen Elizabeth Hospital Norfolk: M Blunt; Royal Sussex Country Hospital ,
Louis: R Lakshmanan; Moses Cone Hospital, Greensboro: P Wright; University of California San Francisco at Fresno, Fresno: K Van Gundy; Rapid City Regional Hospital, Rapid City: J Reyno; Veterans Affairs Medical Center Houston, M Saad. Author details 1 ,
Eli Lilly and Company, Lilly Corporate Centre, 893 South Delaware Street, Critical Care Center, vol.110, issue.3 4, p.8208, 20010. ,
Surviving Sepsis Campaign, Critical Care Medicine, vol.41, issue.2, pp.367-374, 2010. ,
DOI : 10.1097/CCM.0b013e31827e83af
Protein S and C alterations in acutely III patients, American Journal of Hematology, vol.4, issue.1, pp.14-19, 1991. ,
DOI : 10.1002/ajh.2830360104
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis, New England Journal of Medicine, vol.344, issue.10, pp.699-709, 2001. ,
DOI : 10.1056/NEJM200103083441001
Low Levels of Protein C Are Associated With Poor Outcome in Severe Sepsis, Chest, vol.120, issue.3, pp.915-922, 2001. ,
DOI : 10.1378/chest.120.3.915
Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism, Critical Care, vol.8, issue.2, pp.82-90, 2004. ,
DOI : 10.1186/cc2459
Septic Shock, Multiple Organ Failure, and Disseminated Intravascular Coagulation, Chest, vol.101, issue.3, pp.816-823, 1992. ,
DOI : 10.1378/chest.101.3.816
Time Course of Hemostatic Abnormalities in Sepsis and its Relation to Outcome, Chest, vol.103, issue.5, pp.1536-1542, 1993. ,
DOI : 10.1378/chest.103.5.1536
Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications, Critical Care Medicine, vol.28, issue.7, pp.2209-2216, 2000. ,
DOI : 10.1097/00003246-200007000-00005
Critical Care, p.229, 2010. ,
Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated), Critical Care, vol.12, issue.2, p.45, 2008. ,
DOI : 10.1186/cc6854
Severe protein C deficiency predicts early death in severe sepsis, Critical Care Medicine, vol.32, issue.Supplement, pp.223-228, 2004. ,
DOI : 10.1097/01.CCM.0000126120.49367.AC
Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome, Critical Care, vol.10, issue.3, p.92, 2006. ,
DOI : 10.1186/cc4946
Protein C Concentrations Correlate with Organ Dysfunction and Predict Outcome Independent of the Presence of Sepsis, Anesthesiology, vol.107, issue.1, pp.15-23, 2007. ,
DOI : 10.1097/01.anes.0000267531.39410.d3
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial, Intensive Care Medicine, vol.1, issue.6, pp.894-903, 2003. ,
DOI : 10.1007/s00134-003-1731-1
The protein C pathway: implications for the design of the RESPOND study, Critical Care, vol.11, issue.Suppl 5, p.4, 2007. ,
DOI : 10.1186/cc6155
Protein C as a surrogate end-point for clinical trials of sepsis, Crit Care, vol.12, p.139, 2008. ,
The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock*, Critical Care Medicine, vol.35, issue.9, pp.2016-2024, 2007. ,
DOI : 10.1097/01.CCM.0000281637.08984.6E
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*, Critical Care Medicine, vol.33, issue.10, pp.2266-2277, 2005. ,
DOI : 10.1097/01.CCM.0000181729.46010.83
Drotrecogin alfa (activated) for severe sepsis: Could we consider a shorter treatment period in patients with a favorable course?, Journal of Critical Care, vol.24, issue.4, pp.590-594, 2009. ,
DOI : 10.1016/j.jcrc.2009.03.009
Activated protein C: cost matters! Crit Care, p.405, 2010. ,
Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial, Critical Care, vol.13, issue.3, p.83, 2009. ,
DOI : 10.1186/cc7903